In this OncoDaily analysis, OncoBillionaires 2026, we reviewed the Forbes 2026 Billionaires List to identify billionaires whose work, investments, companies, or philanthropic activities intersect with oncology and the broader cancer industry. OncoDaily also explored OncoBillionaires in a previous analysis last year, reflecting the growing connection between global wealth and cancer care.
The final selection includes 28 billionaires from multiple countries, with a combined estimated net worth of more than $162 billion, based on the Forbes 2026 figures used in this analysis.
Who Are the OncoBillionaires 2026?
These figures are not all connected to oncology in the same way. Some are directly tied to cancer drug development and oncology-focused biotechnology, including Robert Duggan, Patrick Soon-Shiong, Ugur Sahin, Leonard Schleifer, John Oyler, George Yancopoulos, Stéphane Bancel, Randal J. Kirk, and Martine Rothblatt. Others have shaped cancer care through vaccines, biosimilars, APIs, generic oncology medicines, and pharmaceutical manufacturing, including Cyrus Poonawalla, Murali Divi, Seo Jung-jin, Pankaj Patel, Sudhir Mehta, Viktor Kharitonin, Tse Ping, Hasmukh Chudgar, Kiran Mazumdar-Shaw, Yusuf Hamied, Alexey Repik, Satish Reddy, G.V. Prasad, Chirayu Amin, and Habil Khorakiwala. A third group represents the infrastructure and investment ecosystem behind modern oncology, including Li Ge, Dennis Gillings, Noubar Afeyan, and Phillip Frost.
Together, these 28 OncoBillionaires show how cancer care is shaped not only by scientists and clinicians, but also by investors, manufacturers, founders, and industrial leaders who influence which therapies are developed, scaled, distributed, and made accessible worldwide. This list is not a ranking of scientific merit or personal virtue. It is a snapshot of how global wealth intersects with oncology innovation, cancer treatment access, and the expanding onco-industry in 2026.
Cyrus Poonawalla – $27 B, India
Cyrus Poonawalla founded and chairs the Serum Institute of India (SII) in 1966, the world’s largest vaccine manufacturer by volume, producing over 1.5 billion doses annually for diseases like polio, measles, DTP, and COVID-19. Son of a horse breeder, he started SII after studying veterinary science at Brihan Maharashtra College of Agriculture, initially exporting horses before pivoting to affordable vaccines for developing nations; his son Adar now serves as CEO, with family control via Cyrus Poonawalla Group including Poonawalla Fincorp (NBFC) and stud farms. Philanthropy through Poonawalla Foundation and Villoo Poonawalla Charitable Foundation supports education, healthcare, disaster relief, and clean water initiatives in Pune.
Serum Institute of India manufactures BCG (Bacillus Calmette-Guérin) vaccine, established as the global standard immunotherapy for non-muscle invasive bladder cancer (NMIBC), administered intravesically post-TURBT to reduce recurrence by 30-40% in high-risk cases. SII’s BCG targets carcinoma in situ (CIS) and papillary tumors (Ta/T1), leveraging attenuated Mycobacterium bovis to induce local immune response via cytokine release (IL-2, IFN-γ), inflammation, and direct cytotoxicity against tumor cells.
This low-cost formulation (~$3-5 per dose) ensures broad access in low-income regions like India and Africa, where NMIBC burdens exceed 70,000 annual cases; SII supplies over 50% of India’s BCG needs, aligning with WHO essential medicines for equitable onco-immunotherapy. No broader cancer drug R&D is pursued; SII’s oncology role remains narrowly focused on this vaccine-derived immunotherapy within its expansive immunization portfolio.
Robert Duggan – $11.6B, United States
Robert Duggan, born in 1944 in Berkeley, California, built his biotech legacy through bold investments and leadership, most notably turning Pharmacyclics into a powerhouse by championing ibrutinib (Imbruvica), a first-in-class BTK inhibitor that transformed treatment for B-cell malignancies like chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström macroglobulinemia. Without a college degree after studying business at UC Santa Barbara and UCLA, he launched Paradise Bakery in 1976 (sold to Panera), Metropolis Media for Eastern Europe advertising (sold for $45M+), and became founding chairman of Computer Motion in 1990, pioneering robot-assisted surgery via the ZEUS system including the historic 2001 Lindbergh Operation—before its 2003 merger into Intuitive Surgical.
Joining Pharmacyclics as chairman/CEO in 2008 amid near-bankruptcy, Duggan invested $26M personally, accelerated Imbruvica’s FDA breakthrough approval in 2013 (second-ever via that pathway), partnered with Janssen, and orchestrated its $21B sale to AbbVie in 2015, netting him over $3.5B in a 70x return.
Today, as CEO of Duggan Investments since 2015, he targets “patient- and physician-friendly” breakthroughs in oncology, antimicrobials, anti-aging, and stem cells; key bets include controlling stakes in Summit Therapeutics (ivonescimab, a PD-1/VEGF bispecific antibody for lung cancer with positive Phase III data boosting shares) and Pulse Biosciences (nsPFA tech for cardiac ablation with onco potential), plus board roles and earlier TaiMed Biologics for HIV/oncology combos. A Scientology donor ($360M+ lifetime), Duggan’s oncology focus persists through high-conviction bets on precision therapies improving survival and quality of life.
Patrick Soon-Shiong – $10.5, United States
Patrick Soon-Shiong, a South African-American surgeon born July 29, 1952, pioneered nanoparticle chemotherapy with Abraxane (nab-paclitaxel), FDA-approved in 2005 for breast cancer and later lung/pancreatic cancers, generating over $1B annual sales via albumin-bound paclitaxel that improves drug delivery and efficacy over traditional taxanes. After medical training at Witwatersrand University and surgical roles pioneering pancreas/islet transplants at UCLA (1980s), he founded VivaGel (1997, HIV microbicide), American Pharmaceutical Partners (2001, injectables for chemo/infectious diseases, sold to Fresenius Kabi for $4.6B in 2008), and Abraxis BioScience (Abraxane commercialization, sold to Celgene for $2.9B in 2010).
In 2011, he launched NantWorks a constellation of 12+ companies including NantHealth (precision oncology via GPS Cancer test), ImmunityBio (Anktiva/N-803 IL-15 agonist approved 2024 for bladder cancer, tripling lung cancer survival in trials, with pancreatic/breast/glioblastoma data), and NantPharma fusing AI, genomics, and immunotherapy for personalized cancer treatment.
Patrick Soon-Shiong stands as a direct inventor and leader in oncology, pioneering chemotherapy standards with Abraxane (nab-paclitaxel, protein-bound paclitaxel for breast, lung, and pancreatic solid tumors, enhancing delivery and efficacy over solvent-based versions). He advances immunotherapy via Anktiva (nogapendekin alfa inbakicept, IL-15 superagonist in combos with BCG for BCG-unresponsive NMIBC and PD-1 inhibitors for NSCLC restoring lymphocytes with OS benefits like 21.1 months in immune-competent responders), plus AI-driven trials tackling immune failures in pancreatic and brain cancers.
His media ownership (LA Times since 2018, Lakers stake) funds the Chan Soon-Shiong Family Foundation’s health initiatives. Soon-Shiong received the 2016 Bower Award for visionary biotech leadership from Abraxane to immunotherapy platforms.
Murali Divi – $10.1B , India
Murali Krishna Prasad Divi, born March 17, 1951, in Machilipatnam, Andhra Pradesh, to a modest government servant family, earned a pharmacy degree from Manipal College of Pharmaceutical Sciences and a PhD in pharmaceutical sciences from Kakatiya University before working as a pharmacist in the U.S., returning to India in the 1980s to partner with Dr. K. Anji Reddy on Cheminor Drugs (acquired 1984).
In 1990, he founded Divi’s Research Centre (now Divi’s Laboratories Ltd.) in Hyderabad with initial Rs 25 lakh capital, scaling it via greenfield factories—first in Choutuppal (1995, generics APIs), second near Visakhapatnam (2002, custom synthesis)—hiring fresh chemistry graduates for cost-efficient, patent-non-infringing processes like enzymatic Naproxen production that won Eli Lilly contracts, rejecting generics-only models to prioritize innovator partnerships.
Divi’s Labs has grown into India’s top API maker and a global CDMO leader (FY25 revenue ₹9,360 crore, net profit ₹2,191 crore), manufacturing high-value generic APIs, intermediates, and nutraceuticals across oncology, cardio, CNS, anti-diabetics exporting to 100+ countries (U.S./Europe/Japan 80%+ revenue) with 15+ manufacturing blocks, peptide expansion (Kakinada Unit-3 operational 2025), and green chemistry emphasis amid China+1 shifts. Family-run: wife Prasanta, children Kiran (executive director), Nilima Motaparti (CFO), son-in-law Prakash Divi.
Direct supply chain powerhouse provides APIs/intermediates for chemotherapy (e.g., generics like docetaxel/paclitaxel), targeted therapies, and supportive care drugs, enabling affordable onco access globally; custom synthesis for innovator cancer pipelines; no proprietary therapeutics but critical backbone (e.g., high-purity peptides for ADCs), ranking among world’s largest API suppliers with oncology as core therapeutic segment.
Divi’s Labs corporate diagram highlights its integrated R&D-to-manufacturing focus spanning oncology APIs.
Low-profile “accidental chemist” Divi emphasizes resilience, innovation over scale, positioning Divi’s for complex molecules amid geopolitical supply realignments.
Seo Jung-jin – $9.9 B, South Korea
Seo Jung-jin founded Celltrion in 2002 after losing his job at an automaker and hearing a scientist discuss biosimilars’ potential, transforming it from a startup into South Korea’s leading biotech firm specializing in affordable biologic copies like Remsima (infliximab for autoimmune diseases), Truxima (rituximab), Herzuma (trastuzumab), and Yuflyma (adalimumab), with U.S./EU approvals driving global sales over $2B annually.
Born around 1965, the self-made entrepreneur without formal science training built Celltrion through aggressive R&D (over 30 biosimilars in pipeline), 2012 IPO, and expansions into new drugs like Zymfentra (first subcutaneous vedolizumab for IBD, 2023 FDA nod) and Eyedaptic (AI eye scanner); he chairs Celltrion Inc., Healthcare, Pharm, and Holdings, co-leading with brother Seo Hong-jin while serving on Korea National Opera board.
Celltrion directly contributes to oncology through its biosimilars portfolio, including Truxima (rituximab) for non-Hodgkin lymphoma and chronic lymphocytic leukemia, Herzuma (trastuzumab) for HER2-positive breast and gastric cancers, and Yory (bevacizumab) for colorectal and lung cancers securing 20-30% market share against originators like Rituxan, Herceptin, and Avastin while cutting costs by 60-80% to broaden access in emerging markets. The pipeline further advances biosimilars for PD-1 inhibitors Keytruda (pembrolizumab) and Opdivo (nivolumab), targeting immuno-oncology expansion.+
Pankaj Patel – $8.2 B , India
Pankaj Ramanbhai Patel chairs Zydus Lifesciences (formerly Cadila Healthcare), India’s fifth-largest pharma company by market cap, which he joined in 1976 after earning pharmacy degrees from Gujarat University and a science/law BA from Mumbai University, taking reins post-1995 family split to transform a debt-laden firm into a global generics/biosimilars/vaccines powerhouse with ₹27,151 crore FY25 revenue. Under his leadership, Zydus pioneered India’s first new chemical entity Lipaglyn (saroglitazar) for diabetic dyslipidemia (2013), launched VaxiFlu-S (first Indian H1N1 vaccine 2009), ZyCoV-D (world’s first DNA-based COVID vaccine 2021), and expanded into 50+ countries via U.S./Europe filings, building the largest Indian vaccine portfolio covering 12+ antigens while acquiring Etanercept biosimilar and filing 400+ ANDAs.
Zydus Lifesciences drives oncology through its generics and biosimilars portfolio, offering chemotherapies like docetaxel, paclitaxel, irinotecan, and oxaliplatin alongside growing targeted therapies and oral oncos, plus supportive care such as anti-emetics all while committing over 8% of revenue to R&D for affordable access and positioning as a key supplier. Phase III trials for bemcentinib (Axl/REceptor inhibitor) target NSCLC and SCLC combinations. As a 2025 Padma Bhushan recipient, Pankaj Patel governs IIMs/Ahmedabad and advances India Pharma Commission standards.
#8 Sudhir Mehta – $8.1B, India
Samir Mehta, born into a Gujarati Jain family around 1964, serves as Executive Chairman of the ₹45,000 crore Torrent Group founded by his father U.N. Mehta in 1959 and has led Torrent Pharmaceuticals since joining in 1986 post-education at Ahmedabad’s School of Business Management, transforming it from a domestic player into a $2B+ revenue global generics leader operating in 40+ countries with 2,000+ registrations.
Under his strategic oversight, key expansions included acquiring Heumann Pharma (Germany, 2005) for European foothold, Elder Pharma (India, 2013) for CNS/generics boost, and Unichem Labs’ domestic business (2017); he invested heavily in R&D (complex generics), state-of-the-art facilities, and niche marketing in cardio, CNS, GI, diabetology, anti-infectives, pain recently passing Indian Pharmaceutical Alliance presidency to Zydus’ Sharvil Patel while projecting India’s pharma growth to $120-130B by 2030.
Torrent Pharmaceuticals maintains a direct and robust oncology portfolio under low-profile leadership, targeting blood cancers with Bortetor (bortezomib injection), Nojetor (lenalidomide 5/10/25mg capsules), and Lymphtor (bendamustine 100mg injection), while addressing solid tumors through Capehope (capecitabine 500mg tablets), Dtaxane/Tortaxel (docetaxel/paclitaxel injections 20-260mg), Torrence (epirubicin injection), Pemotide (pemetrexed 100/500mg), Abatitor (abiraterone 250mg tablets), and Ersteine (everolimus 5/10mg tablets). This lineup emphasizes affordable chemotherapy, targeted therapies, and supportive care tailored for emerging markets, fueled by operational excellence that drives double-digit growth. Torrent Pharma ranks among India’s respected majors in expanding oncology access.
Viktor Kharitonin – $7.9B, Russia
Viktor Kharitonin, born November 20, 1972, in Novosibirsk, chairs Pharmstandard, Russia’s largest pharmaceutical company by revenue, which he co-founded in 2003 alongside Roman Abramovich and Egor Kulkov by consolidating five factories (including ICN Polfa and Veropharm assets), growing it into a generics powerhouse with 250+ products across antibiotics, antivirals, CNS, cardio, diabetes, and oncology.
A Novosibirsk State University economics graduate, Kharitonin entered business via Profit House (1999 securities trading linked to Sibneft/Millhouse), pivoted to pharma recognizing state import substitution needs, listed Pharmstandard on the London Stock Exchange (2008), took it private (2016 via Ogment Investments), and expanded via acquisitions like Gedeon Richter’s Russian assets (2012) and partnerships amid sanctions recently acquiring TSS Group (oil equipment, 2021), Kotlas Chemical Plant (2025), and stakes in Nanolek vaccines.
Pharmstandard upholds a direct and substantial oncology portfolio exceeding 20 cancer therapies, encompassing generics of key chemotherapies like docetaxel, paclitaxel, and cyclophosphamide, alongside supportive care options such as filgrastim (Praestigiac) for neutropenia management and antiemetics, plus targeted agents for broader efficacy. A 2020 partnership with Pfizer localizes innovative treatments for breast, lung, kidney, and leukemia at the Pharmstandard-UfaVITA facility, with first batches rolling out in 2024 to enhance domestic production. The company supplies over 100 essential-list products, dominating Russia’s market through government tenders despite export constraints, as this low-profile oligarch diversifies holdings while sustaining Pharmstandard’s commanding ~25% share in the nation’s pharma landscape.
Li Ge – $7.6B, United States
Li Ge chairs and leads WuXi AppTec, a Shanghai-based global leader in pharmaceutical contract research, development, and manufacturing services (CRDMO), alongside WuXi Biologics, providing end-to-end solutions from drug discovery and preclinical testing to clinical trials and commercial biologics production for 6,000+ clients including Pfizer, Merck, and AstraZeneca, with ~45,000 employees across 30+ sites. A Chinese-American with a PhD in organic chemistry from Columbia University, he founded WuXi AppTec in 2000, scaling it via 2007/2015 IPOs (Shanghai/Hong Kong), WuXi Biologics spin-off (2017), and U.S. expansions amid China+1 trends, generating $5B+ annual revenue through integrated platforms accelerating small molecules, biologics, and cell/gene therapies to market.
WuXi AppTec stands at the center of oncology innovation as a direct enabler, powering over 50% of global oncology pipelines through chemistry synthesis for small-molecule targeted therapies and antibody-drug conjugates (ADCs), alongside biologics manufacturing for monoclonal antibodies like Keytruda and Opdivo biosimilars, and assay development tailored for immuno-oncology breakthroughs. The company supports Phase I-III clinical trials across PD-1/PD-L1 inhibitors, CAR-T therapies, and bispecific antibodies, cementing its role as biotech’s essential “foundry” for cancer advancement amid massive post-COVID capacity expansions. This philanthropic yet low-profile innovator drives Asia’s dominance in biopharma outsourcing for oncology.
Tse Ping – $7.6B, China
Tse Ping founded Sino Biopharmaceutical Limited in 2000 as its Chairman and President, building it into one of China’s largest pharma firms focused on innovative drugs, generics, and traditional Chinese medicine across oncology, anti-infectives, cardio, CNS, metabolism, and respiratory areas, listed on the Hong Kong Stock Exchange with operations spanning CT Tianqing, Beijing Tide Pharmaceutical, and subsidiaries like Jiangsu CT Fenghai/Qingjiang. With 30+ years in Chinese pharma investment/management previously vice-chairman of Shenzhen China Resources Pharmaceutical Group he now serves as Senior Vice Chairman/Executive Director, overseeing R&D for small molecules/biologics while holding senior roles in Charoen Pokphand (CP) Group’s pharma arm and directorships in Shanghai Fortune World and Tianjin Chiatai Feed Tech.
Sino Biopharm maintains direct oncology ties through its robust portfolio, featuring chemotherapy generics like irinotecan and oxaliplatin, targeted therapies, and supportive care drugs produced by subsidiaries such as CT Tianqing to serve China’s vast cancer market with affordable access via domestic manufacturing and state tenders. The pipeline prioritizes novel anti-tumor agents in line with the nation’s innovation drive. This low-profile veteran harnesses CP Group’s resources to fuel integrated pharma growth.
Hasmukh Chudgar – $7.6B, India
Hasmukh Chudgar, born around 1934 into a Jain family in Gujarat, founded Intas Pharmaceuticals Ltd. in 1977 in Ahmedabad as a modest generics venture, spotting unmet needs in affordable formulations amid India’s nascent pharma sector, and steadily scaled it through bootstrapped growth into India’s fourth-largest drugmaker by revenue (~$3.5B FY25 est.) with 20,000+ employees, 16 cGMP facilities across India/UK/US, and exports to 85+ countries before handing day-to-day reins to sons Binish (Chairman/MD), Nimish (Joint MD/CEO), and Rajiv (executive director) while remaining Chairman.
A low-profile self-made pharmacist-entrepreneur with no formal higher education detailed publicly, he prioritized complex injectables and high-barrier generics via strategic acquisitions UCB India (2016, $42M), Accord Pharma’s European assets, Jamp Pharma Canada (2021), and others building integrated R&D/manufacturing for CNS (50% domestic revenue), cardio, oncology, diabetology, nephrology, gastroenterology, urology, pain, rheumatology, ophthalmology, dermatology, gynecology, and infertility, with 2,000+ product registrations globally.
Intas Pharmaceuticals asserts oncology dominance as a direct global leader, producing the world’s top enoxaparin generic (Clexane/Lovenox equivalent, essential for preventing cancer-associated thrombosis), alongside extensive chemotherapy injectables like docetaxel, paclitaxel, irinotecan, oxaliplatin, gemcitabine, and carboplatin, plus biosimilars such as trastuzumab, rituximab (Reditux), and filgrastim (Udenyca, with 2.9x U.S. sales growth in 9MFY26). The portfolio extends to oral targeted therapies and supportive care including anti-emetics and analgesics, accounting for ~20% of revenue across 50+ SKUs that serve the U.S. (via Accord Healthcare), Europe, and India with cost efficiencies from Gujarat mega-plants. This emphasis on patient access in price-sensitive markets underscores its strategic reach.
Ugur Sahin – $4.7B, Germany
Ugur Sahin, born March 19, 1964, in Iskenderun, Turkey, co-founded BioNTech in 2008 with wife Özlem Türeci (CMO) and Uğur Akın (CTO) in Mainz, Germany, building it into a mRNA biotech leader after earlier success at Ganymed Pharmaceuticals where he served as CEO developing EGFR-targeting antibodies IMAB362 (now Zolbetuximab) for gastric cancer, acquired by Sanofi for $1.4B in 2016.
A physician trained at the University of Cologne (MD 1992), he specialized in oncology/internal medicine, pioneering dendritic cell-based cancer vaccines during residency and academic work at Mainz University Medical Center, driven by his mother’s death from cancer to create personalized immunotherapies. BioNTech’s 2019 Pfizer partnership delivered the first mRNA COVID vaccine (BNT162b2/Comirnaty, >$40B sales), funding massive oncology expansion with 20+ clinical programs.
BioNTech’s core mission revolves around revolutionizing cancer treatment through individualized mRNA therapies, highlighted by neoantigen vaccines such as autogene cevumeran (BNT122, in Phase 2 with Moderna for pancreatic cancer, achieving 75% reduced recurrence), BNT111 (melanoma with Phase 2 complete response data), BNT116 (Phase 3 lung cancer), and RO7198457 (personalized tumor vaccines).
The FixVac platform addresses shared antigens in breast and prostate cancers, complemented by next-gen innovations like CAR-T (BNT211 targeting CLDN6), bispecific antibodies (BNT311 as PD-L1 x 4-1BB), and antibody-drug conjugates. Following COVID success, six Phase 3 trials now target melanoma, lung, colorectal, and prostate indications, backed by scaled manufacturing for bespoke doses Sahin forecasts mRNA vaccines as oncology standard by 2030.
Kiran Mazumdar-Shaw – 3.5B, India
Kiran Mazumdar-Shaw founded Biocon in 1978 in her Bangalore garage as India’s first biotechnology company, initially producing enzymes for brewing and agriculture before pivoting to biopharmaceuticals, scaling it into a global leader with $1.5B+ annual revenue, 12,000+ employees, and operations across 120+ countries through strategic partnerships like Clinigene CRO (2000), Syngene research services spin-off (2003), and Biocon Biologics IPO (2022).
Born March 23, 1953, in Bangalore to a brewmaster father, she overcame gender barriers and funding rejections as a 25-year-old brewing graduate (University of Ballarat, Australia) to bootstrap Biocon reaching profitability by 1985 via Unilever’s enzyme joint venture (sold back 2004 for $102M) then aggressively invested in recombinant insulin (world’s first Pichia-based rh-insulin 2004), biosimilars, and novel biologics for diabetes, cancer, autoimmune diseases, emphasizing “patient-centric” affordable innovation amid India’s IP reforms.
Biocon dominates oncology as its core strength, powered by biosimilars such as BOSIYA (trastuzumab for HER2+ breast/gastric cancers, U.S./EU/India approved), BEBEPIZO (bevacizumab for colorectal/non-small cell lung/renal cancers), KRATIZI (rituximab for non-Hodgkin lymphoma/chronic lymphocytic leukemia/RA), and Evertide (everolimus for breast/renal/pancreatic neuroendocrine), alongside chemotherapy generics like paclitaxel and docetaxel plus supportive care. A Viatris partnership drives commercialization across 100+ countries, slashing originator prices 65-80%, while the pipeline pushes ADCs, bispecifics, and cell therapies through Syngene’s 500+ scientist oncology R&D platform. Personally motivated by family cancer losses, Kiran Mazumdar-Shaw established the Mazumdar-Shaw Medical Centre (1,400-bed cancer hospital with 70% subsidized care) and Bangalore Bioinnovation Centre, dedicating 75% of her wealth to philanthropy.
You Can Also Read Phil Knight’s Largest-Ever $2 Billion Donation to OHSU Advances Global Cancer Research by OncoDaily
Leonard Schleifer – $2.8B, United States
Leonard Schleifer co-founded Regeneron Pharmaceuticals in 1988 with George Yancopoulos after earning his MD from Weill Cornell and PhD in immunopharmacology from Rockefeller University, raising $1M initial funding to pioneer protein engineering and monoclonal antibodies using VelocImmune humanized mice and VelociSuite technologies that accelerated discovery of over 30 clinical candidates. Building from early flops like interleukin inhibitors, Regeneron achieved breakthroughs with Eylea (2011, VEGF trap dominating wet AMD with $12B+ peak sales), Dupixent (dupilumab IL-4/13 antibody partnered with Sanofi, $11B+ 2025 sales for atopic dermatitis/asthma/COPD), and COVID antibody REGEN-COV, scaling to $14B+ annual revenue and 15,000 employees across Tarrytown/West Wales sites.
Regeneron’s oncology dominance reflects Schleifer’s strategic vision, anchored by Libtayo (cemiplimab, the first FDA-approved PD-1 inhibitor in 2018 for advanced cutaneous squamous cell carcinoma, later expanded to basal cell carcinoma and NSCLC first-line combos with chemotherapy—delivering a 25% overall survival benefit in Phase 3). Odronextamab (CD20xCD3 bispecific under Priority Review) yields deep remissions in relapsed/refractory follicular lymphoma based on post-regression data, while linvoseltamab (BCMA x CD3) advances in Phase 3 for multiple myeloma with EU/U.S. approvals and a favorable safety profile versus peers.
Emerging assets like REGN1979 (CD20xCD3 for lymphoma), PSMAxCD28 (prostate), MUC16xCD28 (ovarian), and CLDN6xCD28 bispecifics, plus ADCs, leverage the VelocImmune platform for checkpoint-resistant immuno-oncology combos with partners Sanofi and BMS positioning Regeneron as an antibody engineering leader targeting “cold” tumors.
Yusuf Hamied – $2.5B, India
Yusuf Khwaja Hamied, born July 25, 1936, in Vileika (then Poland), serves as non-executive chairman of Cipla Ltd., the generics giant founded by his father Khwaja Abdul Hamied in 1935 amid India’s independence struggle to end British pharmaceutical dependence. Educated at Christ’s College, Cambridge (BA chemistry 1957, PhD organic chemistry 1960 under Nobel laureate Lord Alexander Todd), he joined Cipla in 1960 as R&D director, becoming MD (1976-2013) and pioneering process chemistry to bypass Western patents under India’s 1970 Patents Act famously offering triple AIDS therapy (Triomune) for $350/year in 2001 (vs. $10,000+ branded), treating 6M+ patients globally and earning “the man who made AIDS drugs affordable” moniker.
Cipla grew from enzymes/APIs to $2.5B+ revenue across respiratory (50% sales), HIV, cardio, oncology in 86+ countries via 47 plants, acquisitions (e.g., US distributors), and recent novel drug focus post-TRIPS.
Hamied revolutionized oncology by applying his AIDS playbook to cancer, slashing prices over 75% on sorafenib (Nexavar for kidney/liver cancers) to $175/month versus Bayer’s $5,500, alongside lung/brain therapies like erlotinib, gefitinib, and imatinib for NSCLC/CML, plus generics of paclitaxel, docetaxel, and irinotecan fueling 80+ launches for emerging markets. His “time has come for affordable cancer drugs” ethos prioritizes patient access over profits. As a 2005 Padma Bhushan recipient, this humanitarian capitalism rooted in rejecting “profiteering on disease” has transformed global oncology equity.
Alexey Repik – $2.4B Russia
Alexey Repik, born May 29, 1979, in Novosibirsk, founded R-Pharm in 2001 at age 22 with minimal capital ($40,000 from selling his car and family loans), transforming it from a distribution startup into Russia’s second-largest pharmaceutical company by revenue (~$1.5B+ annually) with 14 production sites, 2,800+ employees, own API/biotech facilities, and international subsidiaries in Germany (R-Pharm Germany), Japan (R-Pharm KK), Turkey, and U.S. offices.
A graduate of Higher School of Economics (economics, 2001), he cut teeth at Rosmedkomplekt (1990s distribution, 10x growth), pivoted to manufacturing recognizing import substitution needs, reinvesting 75%+ profits into greenfield plants (Novosibirsk, Yaroslavl, Irkutsk), R&D centers, and tech transfers from Bayer, Novartis, Roche for antibiotics, oncology, CNS drugs achieving 20%+ CAGR despite Western sanctions limiting exports to domestic/state tenders.
R-Pharma centers its oncology portfolio on direct domestic supply, featuring generics of chemotherapies like docetaxel, paclitaxel, and cyclophosphamide, supportive antibiotics such as levofloxacin for neutropenic sepsis, antineoplastics, and growth factors to bolster Russia’s cancer care through government contracts. Global partnerships enable localized production despite sanctions, with investments in biosimilars and next-gen therapies; while lacking major international brands, it remains a critical access provider locally. As “Business Russia” chairman, Repik pushes energy independence and high-tech while keeping a low profile amid geopolitical pressures.
Phillip Frost – $2.3B United States
Phillip Frost chairs OPKO Health, a diversified diagnostics and therapeutics company he has led since 2007, alongside founding IVAX Corporation (sold to Teva for $7.6B in 2006) building his fortune through generics, biotech investments, and medical devices after a distinguished career as a dermatologist and pharmaceutical executive. Born 1936 in Brooklyn to Russian Jewish immigrants, Frost earned his MD from the University of Cincinnati, completed dermatology residency at University of Miami, invented the disposable punch biopsy tool (widely used in cancer diagnostics), and rose through Key Pharmaceuticals (rhinitis treatments) before launching IVAX in 1987 to capitalize on generics amid patent cliffs.
OPKO Health forges direct oncology ties through its diagnostics-heavy portfolio, led by the 4Kscore blood test a PSA companion that predicts aggressive prostate cancer risk with 30% improved reclassification accuracy, now FDA-approved for men 45+ with abnormal PSA/DRE to guide biopsy decisions and endorsed by NCCN guidelines. Point-of-care tests for tumor markers complement Bio-Reference Laboratories’ oncology lab services (via GenPath), which amassed vast genomics data from GeneDx for drug discovery despite recent non-core asset sales to Labcorp.
Therapeutics include Roxadustat (HIF-PH inhibitor partnered with FibroGen, approved for anemia in CKD and cancer/chemo patients), while EirGen Pharma bolsters biosimilars capacity. Frost’s high-risk strategy favors precision diagnostics over novel drugs, with philanthropy backing University of Miami/Scripps amid SEC trade scrutiny.
Dennis Gillings – $2.2B United Kingdom
Dennis Gillings founded IQVIA (formerly Quintiles) in 1982 as the world’s first CRO, pioneering outsourced clinical trials that revolutionized drug development efficiency for pharma/biotech, scaling it to $15B+ revenue with 88,000 employees across 100+ countries before merging with IMS Health (2016) to create the global leader in real-world evidence, analytics, and technology services. A British-American statistician (PhD Durham University), he started in hospital epidemiology before launching Quintiles from North Carolina, introducing patient recruitment databases, site networks, and Phase I-IV trial management that slashed timelines/costs selling his stake profitably while remaining influential.
IQVIA forges an indirect but foundational oncology correlation, powering over 90% of top pharma trials with real-world data from 10M+ patients across 30+ cancers, AI analytics to forecast success, and HEOR studies enabling market access for immunotherapies, ADCs, CAR-T, and PD-1 therapies. Its biomarker analysis and outcomes research underpin precision oncology payer evidence, serving as essential infrastructure without proprietary drugs.
Stéphane Bancel – $2B, France
Stéphane Bancel has served as CEO of Moderna since 2011, transforming it from a cash-strapped mRNA research firm into a biotech powerhouse valued at $40B+ through relentless execution, raising over $1B pre-IPO and securing BARDA’s landmark $240M 2013 award for pandemic vaccine platforms that funded oncology expansion. A French-American chemical engineer (École des Mines de Paris, Harvard MBA 2000), he built early career success at L’Oréal (mergers), Accenture (strategy consulting), bioMérieux (diagnostics CEO doubling sales), and Lilly Bio-Oncology before joining Moderna to scale lipid nanoparticle (LNP) delivery for non-viral mRNA therapeutics, achieving the mRNA-1273 Spikevax COVID vaccine (FDA EUA Dec 2020, $18.5B 2022 peak sales with GSK) that enabled 40+ clinical programs and global manufacturing at 3B+ doses/year capacity.
Moderna’s post-COVID pivot accelerates its core oncology mission through personalized cancer immunotherapy, led by mRNA-4157/V940 (individualized neoantigen therapy paired with Merck’s Keytruda, where Phase 3 KEYNOTE-942 melanoma data showed 49% reduced risk of recurrence or death and 65% DFS benefit; now expanding into Phase 3 adjuvant NSCLC, colorectal, and immunotherapy-resistant settings).
Next-gen assets like mRNA-4359 (OX40L+IL-2/IL-12 cytokines in Phase 1/2 for solid tumors), mRNA-2752 (intratumoral OX40L+IL-23/IL-36γ to activate “cold” tumors), and combos with PD-1/CTLA-4 inhibitors, ADCs, plus cytokines target ovarian, prostate, and pancreatic cancers. The LNP platform supports repeat dosing without immunogenicity issues, positioning mRNA as the 2030 precision oncology standard beyond checkpoint inhibitors.
Randal J. Kirk – $2B, United States
Randal J. Kirk serves as a serial biotech executive and investor with deep roots in experimental oncology platforms. A lawyer by training (University of Virginia JD), he shifted to biotech leadership, first as CEO and Chairman of Vion Pharmaceuticals from 1995 to 2008, where he championed tumor-microenvironment targeting.
Kirk directed Vion’s ONTARGET platform, engineering Salmonella and E. coli strains to selectively colonize hypoxic tumor cores and deliver cytotoxic payloads like tumor necrosis therapy (TNT, a fusion antibody-toxin exploiting necrotic regions). Clafen (PEGylated TNF-alpha) earned orphan status for glioblastoma multiforme, entering Phase 3 trials with data showing tumor shrinkage in 30-40% of refractory patients before funding collapse led to bankruptcy in 2009.
Transitioning to synthetic biology, Kirk took control of Intrexon (later Precigen) and Ziopharm Oncology (acquired by VG Life Sciences), deploying the RheoSwitch system for inducible gene expression. Flagship asset Ad-RTS-IL-12 + veledimex (an oral controller activating IL-12 cytokine production in tumors) demonstrated durable responses in advanced melanoma (Phase 2 ORR 28%, mPFS 9+ months) and glioblastoma (stable disease in bevacizumab failures), minimizing systemic toxicity via localized, titratable dosing.
Noubar Afeyan – $1.9B, United States
Noubar Afeyan founded Flagship Pioneering in 2000 as a venture creation firm that invents and incubates biotech platforms from first principles, launching over 120 companies—including Moderna (mRNA revolution), Denali Therapeutics (blood-brain barrier for neurodegeneration), Indigo Agriculture (microbiome), and Inari Agriculture (seed engineering) with $50B+ aggregate value created through hypothesis-driven innovation via its VentureLabs R&D engine. Armenian-Lebanese-Canadian born 1962 in Beirut, he fled civil war to Montreal, earned BS/MS chemical engineering from McGill (1983), PhD biochemical engineering from MIT (1987, chromatography thesis), founded PerSeptive Biosystems (pioneering bioprocessing tools, sold to PerkinElmer for $38M in 1998), then built Flagship into a $3.4B+ AUM biotech foundry funding 20-30 ventures yearly while lecturing at MIT Sloan on entrepreneurial innovation.
Flagship Pioneering serves as an indirect oncology enablement powerhouse through VC orchestration, propelling its portfolio with Moderna’s mRNA cancer vaccines like mRNA-4157 (neoantigen therapy in Phase 3 melanoma with Keytruda, delivering 44-65% risk reduction) and mRNA-4359 (cytokines for solid tumors). Recursion Pharmaceuticals leverages AI for oncology hits, Rubius Therapeutics engineers red cells for immuno-oncology, and Sera Prognostics advances cell reprogramming among 40+ ventures pushing ADCs, bispecifics, and gene therapies. Afeyan champions “platform medicines” and regulatory acceleration for individualized cancer cures, while cautioning against U.S. biotech leadership slipping to China.
John Oyler – $1.9B, United States
John Oyler co-founded BeiGene (now BeOne Medicines) in 2010 with biochemist Xiaodong Wang, building it from a $10M startup into a $20B+ global oncology powerhouse focused on affordable, innovative cancer therapies through in-house clinical trials, manufacturing, and partnerships with Amgen, Pfizer, and Organon. Born April 3, 1968, the MIT dropout serial entrepreneur previously founded Telephia (wireless analytics, sold to Nielsen for $449M in 2007), BioDuro CRO (sold to PPD for $77M in 2009), and served as oncology co-CEO at Genta, leveraging China operations for cost-effective R&D while listing on Nasdaq (2016), Hong Kong (2018), and Shanghai STAR (2021) to fund a pipeline addressing unmet needs in blood/solid tumors.
BeiGene exemplifies oncology leadership under direct pioneering, with over a dozen approved therapies including Brukinsa (zanubrutinib BTK inhibitor, outpacing Imbruvica in lymphoma sales and securing frontline CLL approval via superior PFS in head-to-head trials) and Tevimbra (tislelizumab PD-1 inhibitor for esophageal squamous cell carcinoma and NSCLC). Its integrated model has treated 1.5M+ patients globally, cutting costs 50-70% versus Western peers through ADCs and combos, with Phase 3 readouts pending in gastric, liver, and colorectal cancers to boost Asia-Pacific access.
George Yancopoulos – $1.8B, United States
George Yancopoulos co-founded Regeneron Pharmaceuticals in 1988 with Leonard Schleifer and serves as President & Chief Scientific Officer, inventing its core technologies—VelocImmune (fully humanized antibody mice producing 100+ clinical candidates), VelociGene (mega-base genetic engineering), and TRAP (soluble receptor fusion proteins) driving 10+ FDA-approved blockbusters including Eylea ($12B+ peak VEGF for AMD), Dupixent ($11B+ IL-4/13 for atopic dermatitis/asthma), and Libtayo (PD-1 for skin/lung cancers).
Greek-American born 1959, he earned MD/PhD from Columbia (1985, immunology thesis), completed residency at NYU/Bellevue, then joined Regeneron as its first scientist—holding 125+ patents and pioneering antibody engineering that bypassed nonhuman immunogenicity issues, enabling rapid discovery of bispecifics/cocktails (REGN-EB for Ebola, REGN-COV2 for COVID).
Regeneron demonstrates oncology mastery through Libtayo (cemiplimab, the first PD-1 approved in 2018 for cutaneous squamous cell carcinoma and now frontline NSCLC chemo combo with OS benefit), odronextamab (CD20xCD3 bispecific for follicular lymphoma under Priority Review), and linvoseltamab (BCMA x CD3 with 71% ORR in Phase 3 multiple myeloma).
Emerging bispecifics like PSMAxCD28 (prostate), MUC16xCD28 (ovarian), and CLDN6 target “cold” tumors, powered by VelocImmune for Sanofi/BMS immuno-oncology combos transcending checkpoints. From Regeneron’s NYC office, Yancopoulos oversees antibody platforms driving this expansive oncology pipeline.
Martine Rothblatt – $1.7B, United States
Martine Rothblatt chairs and leads United Therapeutics Corporation (UTHR), which she founded in 1996 after her daughter’s diagnosis with pulmonary arterial hypertension (PAH)—a then-fatal orphan lung disease developing Remodulin (treprostinil subcutaneous 2002, FDA-approved first new PAH therapy in 25 years), Tyvaso (inhaled 2009), Orenitram (oral 2013), and Uptravi (selexipag 2015), generating $2.5B+ annual revenue with four approved formulations dominating 60%+ U.S. PAH market share.
Born Martin Rothblatt 1954, she earned combined JD/MBA from UCLA (1981), pioneered satellite communications (SiriusXM founder, global orbit/spectrum treaties), underwent gender transition surgery (1994), and pivoted to biotech via crash-course medical ethics PhD (2001, Queen Mary London) focused on xenotransplantation ethics—now advocating transhumanism while serving Mayo Clinic board.
Oncology correlation: Indirect—UTHR’s Unituxin (dinutuximab monoclonal antibody for high-risk neuroblastoma in children, FDA-approved 2014 via accelerated pathway, $100M+ peak sales) represents its sole cancer product; core focus remains cardiopulmonary orphan diseases with xenokidney/lung programs (UK 2024 pig-to-human transplant) and 3D-printed lung scaffolds, not broad oncology R&D.
Rothblatt at a 2024 event, blending biotech leadership with transhumanist advocacy.
Highest-paid female CEO historically, her “geoethics” philosophy balances innovation with access for rare diseases.
Satish Reddy – $1.6B, India
Satish Reddy chairs Dr. Reddy’s Laboratories, a global generics and biosimilars powerhouse founded by his late father Kallam Anji Reddy in 1984, which he joined in 1993 as Executive Director—rising through Managing Director (1997) and Vice Chairman/MD (2013) to lead its evolution from API manufacturing to finished dosage formulations with $3.5B+ revenue across 500+ products in 50+ countries. Chemical engineering graduate (Osmania University) with MS in medicinal chemistry (Purdue), Reddy drove U.S./Europe expansions, Russia/CIS dominance (Betapharm acquisition), and complex generics in oncology, gastro, cardio while shaping India’s pharma policy as Indian Pharmaceutical Alliance past president.
United Therapeutics’ oncology correlation is indirect, centered on Unituxin (dinutuximab, a monoclonal antibody FDA-approved via accelerated pathway in 2014 for high-risk neuroblastoma in children post-induction therapy generating $100M+ peak sales when combined with GM-CSF, IL-2, and 13-cis-retinoic acid to extend event-free survival by ~30%).
Its core remains cardiopulmonary orphans, including xenokidney (UKidney™ world-first pig-to-human transplant 2024) and lung programs like 3D-printed scaffolds plus 500th EVLP transplant milestone. Rothblatt, blending biotech leadership with transhumanist advocacy at 2024 events, embodies “geoethics” as history’s highest-paid female CEO prioritizing rare disease access over broad oncology R&D.
G.V. Prasad – $1.6B, India
G.V. Prasad serves as Co-Chairman and Managing Director of Dr. Reddy’s Laboratories alongside Satish Reddy, driving its transformation into a $3.5B+ revenue global generics/biosimilars leader since joining in 1990 with chemical engineering (IIT Madras) and MBA (SPJIMR) credentials. Prasad spearheaded U.S. growth via first-to-file ANDAs, European acquisitions (Betapharm 2008), and Russia/CIS dominance while championing complex generics in oncology, CNS, and cardiovascular segments, positioning Dr. Reddy’s as India’s third-largest pharma exporter.
The company’s oncology focus shines through its direct portfolio strength, featuring generics like olaparib (PARP inhibitor for ovarian/breast cancers), abiraterone acetate (prostate cancer), gefitinib/erlotinib (EGFR inhibitors for NSCLC), and chemotherapy staples such as paclitaxel/docetaxel. A biosimilars pipeline for trastuzumab and rituximab targets first-to-market edges, while supportive care—including anti-emetics and growth factors prioritizes affordability in emerging markets, driving 20%+ segment growth.
Chirayu Amin – $1.5B, India
Chirayu Amin chairs Alembic Pharmaceuticals Ltd., a 190+ year-old Indian firm he has led as Chairman & CEO (until March 2026, now Executive Chairman), transforming it into a $1.5B+ revenue generics/biosimilars player focused on respiratory, anti-infectives, dermatology, and oncology with exports to 75+ countries via facilities in Vadodara and Gujarat. Born into the founding Leva Patel business family in Vadodara, Gujarat, he holds a BSc from Maharaja Sayajirao University of Baroda and MBA from Seton Hall University (USA), driving Alembic’s U.S./Europe growth through first-to-file ANDAs, API integration, and complex generics while serving as ex-IPL Chairman, BCCI Vice President, and FICCI Gujarat head.
The company contributes directly to oncology via generics of chemotherapy agents like gefitinib (for NSCLC) and imatinib (for CML), alongside supportive care such as anti-emetics and analgesics. Its pipeline of biosimilars targets trastuzumab and rituximab, supplying affordable access in India and emerging markets through government tenders accounting for ~10-15% of revenue while advancing U.S. ANDA filings.
Habil Khorakiwala – 1.3$, India
Habil Khorakiwala chairs Wockhardt Ltd., an Indian multinational pharma firm founded by his father H.F. Khorakiwala in 1919, which he transformed from a commodity antibiotics producer into a $1B+ revenue innovator in generics, biosimilics, and novel biologics with global operations in the UK, Ireland, U.S., and India. Chemical engineer (IIT Bombay) with MBA (Temple University), Khorakiwala drove strategic pivots like acquiring CP Pharmaceuticals (UK, 1996), Esparma (Germany), and building Chikalthana’s sterile injectables campus emphasizing high-barrier molecules in respiratory, anti-infectives, oncology, and diabetology while navigating debt challenges through asset sales.
Wockhardt plays a direct role in oncology via its biosimilars portfolio, featuring Nimotuzumab (EGFR monoclonal antibody approved in Cuba and India for head/neck cancers) and HD201 (trastuzumab biosimilar with positive Phase III data demonstrating equivalence to Herceptin in efficacy, PK, and safety for HER2+ early breast cancer). It complements these with chemotherapy generics like paclitaxel, docetaxel, and oxaliplatin, plus supportive care, supplied affordably to EU/U.S. markets from UK plants positioning Khorakiwala as a biosimilar pioneer amid 2020s financial headwinds․
You Can Also Read OncoBillionaires of 2025: The Titans Behind the Cancer Revolution by OncoDaily
Written by Aharon Tsaturyan, MD, Editor at OncoDaily Intelligence Unit